CN103025760A - 人源化egfr抗体 - Google Patents

人源化egfr抗体 Download PDF

Info

Publication number
CN103025760A
CN103025760A CN2011800364375A CN201180036437A CN103025760A CN 103025760 A CN103025760 A CN 103025760A CN 2011800364375 A CN2011800364375 A CN 2011800364375A CN 201180036437 A CN201180036437 A CN 201180036437A CN 103025760 A CN103025760 A CN 103025760A
Authority
CN
China
Prior art keywords
antibody
variable region
seq
aminoacid sequence
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800364375A
Other languages
English (en)
Chinese (zh)
Inventor
S·戈莱茨
A·丹尼尔奇克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glycotope GmbH
Original Assignee
Glycotope GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycotope GmbH filed Critical Glycotope GmbH
Publication of CN103025760A publication Critical patent/CN103025760A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN2011800364375A 2010-08-10 2011-08-10 人源化egfr抗体 Pending CN103025760A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US37218610P 2010-08-10 2010-08-10
US61/372,186 2010-08-10
EP10008319.5 2010-08-10
EPPCT/EP2010/004880 2010-08-10
EP2010004880 2010-08-10
EP10008319 2010-08-10
PCT/EP2011/063781 WO2012020059A1 (fr) 2010-08-10 2011-08-10 Anticorps anti-egfr humanisés

Publications (1)

Publication Number Publication Date
CN103025760A true CN103025760A (zh) 2013-04-03

Family

ID=44510957

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800364375A Pending CN103025760A (zh) 2010-08-10 2011-08-10 人源化egfr抗体

Country Status (4)

Country Link
EP (1) EP2603527A1 (fr)
CN (1) CN103025760A (fr)
BR (1) BR112013003257A2 (fr)
WO (1) WO2012020059A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105229030A (zh) * 2013-04-22 2016-01-06 葛莱高托普有限公司 用具有低岩藻糖基化的抗-egfr抗体的抗-癌治疗
CN109415441A (zh) * 2016-05-24 2019-03-01 K·E·格里斯沃尔德 抗体及其制备方法
CN111171151A (zh) * 2019-12-26 2020-05-19 佛山汉腾生物科技有限公司 抗egfr纳米抗体及其应用
CN112300278A (zh) * 2019-07-25 2021-02-02 上海交通大学 抗人egfr嵌合抗体及其制备方法和用途

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140170159A9 (en) 2012-03-08 2014-06-19 Ge Wei Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
US9921222B2 (en) 2012-07-31 2018-03-20 Crown Bioscience, Inc. (Taicang) Histological markers for identifying non-small cell lung carcinoma patients for treatment with an anti-EGFR drug
US9777067B2 (en) 2012-09-27 2017-10-03 Massachusetts Institute Of Technology HER2- and VEGF-A-binding proteins with enhanced stability
EA201600252A1 (ru) 2013-09-12 2017-05-31 Галозим, Инк. Модифицированные антитела к рецепторам антиэпидермального фактора роста и способы их использования
WO2017161206A1 (fr) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugués contenant des anticorps à activité conditionnelle ou des fragments de liaison à un antigène associés, et procédés d'utilisation
WO2023166098A1 (fr) 2022-03-02 2023-09-07 Biomunex Pharmaceuticals Anticorps bispécifiques se liant à her-3 et à her-2 ou egfr

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100056762A1 (en) * 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
US7241444B2 (en) * 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
DK2073842T4 (da) 2006-09-10 2024-01-15 Glycotope Gmbh Anvendelse af humane celler af myloid leukæmioprindelse til udtrykkelse af anti-stoffer

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105229030A (zh) * 2013-04-22 2016-01-06 葛莱高托普有限公司 用具有低岩藻糖基化的抗-egfr抗体的抗-癌治疗
CN109415441A (zh) * 2016-05-24 2019-03-01 K·E·格里斯沃尔德 抗体及其制备方法
CN109415441B (zh) * 2016-05-24 2023-04-07 英斯梅德股份有限公司 抗体及其制备方法
US11649291B2 (en) 2016-05-24 2023-05-16 Insmed Incorporated Antibodies and methods of making same
CN112300278A (zh) * 2019-07-25 2021-02-02 上海交通大学 抗人egfr嵌合抗体及其制备方法和用途
CN111171151A (zh) * 2019-12-26 2020-05-19 佛山汉腾生物科技有限公司 抗egfr纳米抗体及其应用
CN111171151B (zh) * 2019-12-26 2021-09-14 佛山汉腾生物科技有限公司 抗egfr纳米抗体及其应用

Also Published As

Publication number Publication date
BR112013003257A2 (pt) 2016-06-14
EP2603527A1 (fr) 2013-06-19
WO2012020059A1 (fr) 2012-02-16

Similar Documents

Publication Publication Date Title
CN103025760A (zh) 人源化egfr抗体
TWI708788B (zh) 雙特異性抗體
AU2010242914B2 (en) Improved antibodies immunoreactive with heregulin-coupled HER3
US8937159B2 (en) Anti-HER2 antibodies and their uses
US8658175B2 (en) Anti-EGFR antibodies and their uses
CN103153331B (zh) 靶向于钙粘着蛋白‑11的ec1结构域的人源化抗体及相关组合物和方法
CN104093743A (zh) 特异于her3的结合分子及其用途
CN105829345A (zh) 结合egfr和met的多功能抗体
US20200291130A1 (en) Antibodies for the treatment of erbb-2/erbb-3 positive tumors
US20220340657A1 (en) Antibody and bispecific antibody targeting lag-3 and use thereof
TW201904999A (zh) 抗gitr抗體、其抗原結合片段及其醫藥用途
JP7430137B2 (ja) 抗体および使用方法
US9051370B2 (en) Humanized EGFR antibodies
TW202039571A (zh) Muc18特異性抗體
AU2022273136A1 (en) Binding molecule against dll3 and use thereof
CN116769034A (zh) 抗cd73抗体或其抗原片段及其应用
CN110382541A (zh) 人源化抗cd40抗体
CN114746443A (zh) 抗gdf15抗体
US9464136B2 (en) Antibody-based constructs directed against tyrosine kinase receptors
WO2024046245A1 (fr) Anticorps anti-pvrig et application correspondante
RU2735102C1 (ru) Антитело, специфично связывающееся с белком PAUF, и его применение
KR20240024061A (ko) 항-EGFRvIII 항체 약물 접합체 및 이의 용도
AU2021307516A1 (en) Anti-CLDN-18.2 antibody and use thereof
KR20240049829A (ko) 항-4-1bb 나노바디
CN117586390A (zh) 抗cgrp抗体及用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130403